- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02181283
MiSSION STRONG - Preventing AOS Misuse in the National Guard
Preventing Alcohol/Prescribed Drug Misuse in the National Guard: Web and Peer BI
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Individuals will be eligible to participate if they are in the Michigan Army National Guard and their unit is selected to participate in the proposed study. Individuals will be eligible to participate in the randomized trial if they:
- have an AUDIT-C score of 5 or more for men and 4 or more for women in the prior 4 months, indicating that they meet criteria for at-risk drinking/alcohol misuse; and/or
- use of prescribed opioids or sedatives in the prior 4 months in a manner that was inconsistent with their prescribed course of treatment (medical misuse: determined by items from an adapted PMQ).
Exclusion Criteria:
- under 18 years of age
- inability to speak and understand English
- inability to give informed, voluntary consent
- do not have access to the Web (e.g. home, work, library, WiFi-enabled tablet PCs (iPad), etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: W+W
Web-delivered alcohol/prescribed drug misuse brief intervention with Web booster sessions (W+W).
|
Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored "change plan". Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps.
Other Names:
|
|
ACTIVE_COMPARATOR: W+P
Web-delivered brief intervention with Peer-delivered booster sessions (W+P).
|
Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored "change plan". Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support.
Other Names:
|
|
NO_INTERVENTION: Enhanced Usual Care
Enhanced usual care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alcohol use
Time Frame: change over time (4-, 8- and 12-months post baseline)
|
The full AUDIT which includes the AUDIT-C, will be used to assess alcohol use.
Quantity and frequency is measured by number of drinking days, number of drinks per day and number of binge drinking days.
Alcohol related consequences are measured using the modified SIP.
|
change over time (4-, 8- and 12-months post baseline)
|
|
Medical misuse of opioids or sedatives
Time Frame: change over time (4-, 8- and 12-months post baseline)
|
Quantity and frequency is measured by number of days misused, and the NIDA-Modified ASSIST and adapted Pain Medication Questionnaire (PMQ) are used to assess medical misuse of prescribed opioids and medical misuse of prescribed sedatives.
Consequences are measured using the modified SIP.
|
change over time (4-, 8- and 12-months post baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Consequences of AOS use, including a) injury, b) mental and physical health functioning, and c) HIV-risk behaviors
Time Frame: 4-, 8- and 12-months post baseline
|
3a) Injury is measured using the Revised Injury Behavior Checklist (RIBC). 3b) Mental and physical health functioning is measured using a brief version of the Short Form Health Survey (SF-12), the Generalized Anxiety Disorder (GAD-7) questionnaire, the Patient Health Questionnaire (PHQ), the Post-Traumatic Disorder Checklist-Military Version (PCL-5) and items from the Unit Risk Inventory, developed by the Army Substance Abuse Program. 3c) HIV-risk behaviors are measured using questions from the HIV Risk-Taking Behavior Scale (HRBS). |
4-, 8- and 12-months post baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AA023122
- 1R01AA023122-01 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AOD Misuse
-
Assistance Publique - Hôpitaux de ParisCompleted
-
RANDNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAOD Misuse | AOD Associated ConsequencesUnited States
-
Rennes University HospitalMinistry of Health, FranceTerminatedAlcohol Abuse | Alcohol Problem | AOD MisuseFrance
-
Karolinska InstitutetCompleted
-
Mclean HospitalTerminatedAOD Effects and ConsequencesUnited States
-
University of California, San FranciscoCompletedAOD Use, Abuse, and DependenceUnited States
-
University of CologneUmm Al-Qura UniversityCompletedAOD Effects and ConsequencesGermany
-
University of BirminghamNewcastle University; National Institute for Health Research, United Kingdom; University of York and other collaboratorsUnknownAlcohol Misuse | Drug Misuse
-
Université de Reims Champagne-ArdenneNot yet recruiting
-
mHealth Systems Inc.Boston Children's Hospital; University of North Carolina, CharlotteRecruitingAlcohol Misuse | Cannabis MisuseUnited States
Clinical Trials on W+W
-
GlaxoSmithKlineCompleted
-
Mimetica Pty LimitedUnknownAcne VulgarisUnited States
-
Mimetica Pty LimitedCompleted
-
Amytrx Therapeutics, Inc.Amarex Clinical ResearchCompletedAtopic DermatitisUnited States
-
Aclaris Therapeutics, Inc.CompletedAtopic DermatitisUnited States
-
Pharma Holdings ASUniversity Hospital of North NorwayCompleted
-
Zai Lab (Hong Kong), Ltd.Zai Lab (US) LLCRecruiting
-
U.S. Army Medical Research and Development CommandCompletedGingivitis | PlaqueUnited States
-
DS BiopharmaCompletedAtopic DermatitisUnited States, Canada, South Africa
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States